Screener / SEC EDGAR /CIK 0001649904 /10-K filed Feb 26, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Rhythm Pharmaceuticals, Inc. RYTM

Compare with peers Embed
Why it changed

The biggest changes in the 10-K filed Feb 26, 2026, in management's words

10-K, Item 7

This fiscal year against the last, and the sentences in the MD&A where management explains each change. Tickdelta picks sentences that name the line, a direction and a cause. It does not write explanations of its own.

Operating margin

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

-204.0% to -101.2% (+102.8 pts)

The MD&A has no sentence that names a cause for this change.

Revenue

Big change, FY to Dec 31, 2025 vs Dec 31, 2024

+45.8%

“Product revenue, net increased by $64.6 million to $194.8 million in 2025 from $130.1 million in 2024, an increase of 50%, due primarily to higher volume of product sold both domestically and internationally.”

Read it in the 10-K

“Cost of sales increased by $6.1 million to $19.5 million in 2025 from $13.4 million in 2024, an increase of 46%, which was driven primarily by the increase in product revenue in 2025.”

Read it in the 10-K

What management said, year by year

The cause given in each 10-K, 2 fiscal years, newest first · MD&A (Item 7)

Each bar is how the line changed that year (from the same 10-K's XBRL). Under it, the sentence in that year's MD&A that names the line, a direction and a cause, word for word. A year with no sentence says so.

Revenue

2 of 2 years explained
  • FY 2025 +45.8%

    “Product revenue, net increased by $64.6 million to $194.8 million in 2025 from $130.1 million in 2024, an increase of 50%, due primarily to higher volume of product sold both domestically and internationally.”

    Read it in the FY 2025 10-K

    “Cost of sales increased by $6.1 million to $19.5 million in 2025 from $13.4 million in 2024, an increase of 46%, which was driven primarily by the increase in product revenue in 2025.”

    Read it in the FY 2025 10-K
  • FY 2024 +68.1%

    “Cost of sales increased by $4.1 million to $13.4 million in 2024 from $9.3 million in 2023, an increase of 44%, which was driven primarily by the increase in product revenue in 2024.”

    Read it in the FY 2024 10-K

    “Specifically, the $4.1 million increase in cost of sales in 2024 was due to $2.6 million of additional royalties due to our growth in sales and $1.5 million due to higher product costs from higher net product revenue.”

    Read it in the FY 2024 10-K

Operating margin

0 of 2 years explained
  • FY 2025 +102.8 pts

    The FY 2025 MD&A has no sentence that names a cause for this change.

  • FY 2024 +34.1 pts

    The FY 2024 MD&A has no sentence that names a cause for this change.

Changes are computed from the XBRL figures in the same 10-K. Hover a number to see the line item. Open the 10-K

Sources

The Management's Discussion and Analysis (Item 7) of the latest 10-K, quoted word for word; the changes are computed from the same 10-K's XBRL.

Also

Financials: the numbers year by year.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RYTM/export.csv") into a cell.

Next:Accounting checks
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.